Elicio Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $29.83M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $-0.43 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | $-0.65 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-0.60 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | $-0.66 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-0.87 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | $-1.39 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | $-0.64 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | $1.15 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | Before market open | – | – | – |
Press releases
Announcements Elicio Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $15 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Metastatic mKRAS PDAC JUNE 24, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
LifeSci Communications (415) 269-7757 [email protected]
Other events · EX-99.1 to Form 8-K
LifeSci Communications (415) 269-7757 [email protected]
Other events · EX-99.1 to Form 8-K
AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Adjuvant mKRAS PDAC JUNE 15, 2026
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 2025 AMPLIFY-7P Phase 2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Relations Contact Brian Ritchie LifeSci Advisors (212) 915-2578 [email protected]
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Targeting the Lymph Nodes to AMPlify Immunotherapy Nasdaq: ELTX January 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Targeting the Lymph Nodes to AMPlify Immunotherapy Nasdaq: ELTX December 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Elicio Therapeutics Announces Closing of Private Placement of
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
of $11.5 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Elicio Therapeutics Announces Preliminary Disease-Free
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeting the Lymph Nodes to AMPlify Immunotherapy Nasdaq: ELTX June 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
Other events · EX-99.1 to Form 8-K
Targeting the Lymph Nodes to AMPlify Immunotherapy January 2024
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K